BioLineRx Ltd. Announces First Subject Enrolled in Phase I Clinical Trial of BL-1021 for Neuropathic Pain
7/6/2011 10:30:37 AM
JERUSALEM--(BUSINESS WIRE)--BioLineRx (TASE:BLRX) announced today the enrollment of the first subject in a Phase I study of BL-1021, an orally available small molecule for treating neuropathic pain. This clinical trial will be a first-in-human, single-site, double-blind, placebo controlled study to assess safety, tolerability and pharmacokinetics of BL-1021 in healthy volunteers. The primary endpoints of the study are to examine the safety and tolerability of a single administration or multiple administrations of BL-1021, and the secondary endpoints are the pharmacokinetics of single or multiple doses of BL-1021 in healthy subjects. The study will be carried out at the Hadassah Clinical Research Center (HCRC) in Jerusalem, Israel, led by Principal Investigator Professor Yoseph Caraco, and is expected to enroll up to 56 subjects.